BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:05 PM
Jun 26, 2008
 |  BC Extra  |  Clinical News

Vanda falls on tasimelteon data

Vanda (NASDAQ:VNDA) fell $0.79 (16%) to $4.20 on Thursday after the melatonin receptor agonist met the primary endpoint but missed certain secondary endpoints in a Phase III trial to treat chronic insomnia. In the double-blind trial in 322 patients, both doses of tasimelteon (20 and 50 mg) significantly improved latency to persistent sleep (LPS) on nights...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >